Vildagliptin also proved its effect against the inflammatory milieu, by increasing adiponectin and lowering the inflammatory markers tested, effects that are recently documented in a Parkinson's disease model [64] and in diabetic patients [79, 80]. This evidence concerns the gene ADIPOQ and Parkinson disease.